Boston Scientific (BSX) Stock
Global medical device company powering heart and urology care. Here's the price, business snapshot, and what's worth knowing about Boston Scientific in August 2026.
Boston Scientific (BSX) is a global medical‑devices company with a market capitalisation of about $148.03bn, selling products used in cardiology, rhythm management, peripheral interventions, endoscopy and urology. Investors should know it earns recurring revenue from disposable devices and procedure-driven demand, backed by ongoing R&D and product launches. The business benefits from demographic trends such as an ageing population and wider access to minimally invasive therapies, yet it faces stiff competition from large peers, reimbursement and regulatory pressures, and occasional product or legal setbacks. Financial performance can be influenced by procedure volumes, hospital capital spending, foreign exchange and the success of new technologies. For investors, Boston Scientific offers exposure to healthcare innovation but also to sector-specific operational and regulatory risks. This is general educational information, not personalised advice — values can rise and fall and past performance is not a reliable guide to future returns.
Why It’s Moving
BSX is moving as investors weigh a softer outlook against signs of underlying operating strength.
- Boston Scientific has been under pressure after its late-July outlook disappointed investors, with the company flagging slower growth in some key devices and a softer 2026 forecast.
- Recent commentary has focused on execution risk in the WATCHMAN franchise and other growth drivers, which has tempered enthusiasm even after the prior quarter’s revenue and earnings beat.
- At the same time, insider buying and a steady stream of bullish analyst notes have helped stabilize sentiment, suggesting some investors still see room for a rebound if product momentum improves.
BSX is moving as investors weigh a softer outlook against signs of underlying operating strength.
- Boston Scientific has been under pressure after its late-July outlook disappointed investors, with the company flagging slower growth in some key devices and a softer 2026 forecast.
- Recent commentary has focused on execution risk in the WATCHMAN franchise and other growth drivers, which has tempered enthusiasm even after the prior quarter’s revenue and earnings beat.
- At the same time, insider buying and a steady stream of bullish analyst notes have helped stabilize sentiment, suggesting some investors still see room for a rebound if product momentum improves.
Sixth Month Growth Performance
next-earnings-question
The next expected earnings date for BSX is October 28, 2026. It is expected to cover Q3 2026 results and is typically reported before the market opens. This timing is consistent with Boston Scientific’s historical quarterly reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Boston Scientific stock with a target price of $81.74, indicating strong growth potential.
Financial Health
Boston Scientific is performing well with solid revenue, profits, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Procedure demand tailwind
An ageing population and rising access to minimally invasive procedures can support long‑term demand, though volumes can ebb with hospital spending cycles.
Innovation and R&D
Regular product launches and technological improvements drive share gains and pricing power, but new products must clear regulatory and commercial hurdles.
Regulatory and market risks
Exposure to reimbursement, recalls and litigation means performance can be volatile; investors should weigh potential returns against these sector‑specific risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
